Actualités XBiotech Inc - XBIT | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Current Report Filing (8-k)

00-0000000 0001626878 false 0001626878 2023-02-03 2023-02-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Quarterly Report (10-q)

0001626878 XBiotech Inc. false --12-31 Q3 2022 0 0 Unlimited Unlimited 30,439,277 30,439,277 250,834 4.5 0 0 0 0 1 2,924 0...

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of...

Quarterly Report (10-q)

0001626878 XBiotech Inc. false --12-31 Q2 2022 0 0 Unlimited Unlimited 0 0 0 0 Unlimited Unlimited 30,439,275 30,439,275 266,46...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

AUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Proxy Statement (definitive) (def 14a)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

XBiotech Inc (XBIT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

XBIT Actualités

Additional Proxy Soliciting Materials (definitive) (defa14a)

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Quarterly Report (10-q)

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Quarterly Report (10-q)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

XBiotech Inc (XBIT) Actualités

XBiotech Inc (XBIT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

XBIT Actualités

Additional Proxy Soliciting Materials (definitive) (defa14a)

Current Report Filing (8-k)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Statement of Ownership (sc 13g)

Quarterly Report (10-q)

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Quarterly Report (10-q)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application